# Lexicon Pharmaceuticals Inc. (LXRX) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $2.24, market value $997 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Lexicon Pharmaceuticals Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 24.0×**. Each dollar of revenue is priced at 24.0×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 5.7×**. The shares trade at 5.7× book value; most of the value is in earnings power and intangibles rather than the balance sheet.

## Profitability
- **Operating margin: -131.4%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -101.1%**. The company reported a net loss over the last twelve months.
- **Return on equity: -46.8%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -33.8%**. Return on all capital, debt included, is -33.8%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -33.0%**. Each dollar of assets produces -33.0% of profit.

## Growth
- **Revenue growth (1 yr): 729.9%** (5-yr 16.3%/yr). Revenue grew 729.9% over the last year, against 16.3% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 77.8%**. Earnings per share rose 77.8%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.50**. Debt is 0.50 times equity, moderate leverage.
- **Net debt / EBITDA: net cash**. Lexicon Pharmaceuticals Inc. holds more cash than debt.
- **Altman Z-score: 7.93**. A Z-score of 7.93 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Lexicon Pharmaceuticals Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (5 analysts). 5 analysts cover Lexicon Pharmaceuticals Inc.; the consensus is buy, with an average price target of $3.86 (+72% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 109.3%** (YTD 94.8%, 3-mo 17.3%). The shares are up 109.3% over twelve months including dividends.
- **From 52-week high: -16.4%** (111.3% above the low). Trading 16% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 46**. An RSI of 46 is neutral.
- **Beta (1 yr): 1.51** (volatility 77%). Beta of 1.51 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=LXRX · Page: https://foliofundamentals.com/stocks/lxrx

Not investment advice.